Gunderson Dettmer represented client Alumis, formerly known as Esker Therapeutics, a precision immunology company, which is backed and incubated by Foresite Labs, in its $200 million Series B financing led by AyurMaya, an affiliate of Matrix Capital Management. Alumis uses data analytics and research capabilities to build a pipeline from internal and external sources to deliver precision immunology therapies impacting the causal drivers of multiple autoimmune disease indications. The new capital will enable the company to advance the development of ESK-001 for the treatment of psoriasis.

In the announcement of the transaction, President and CEO of Alumis Martin Babler said, “We are thrilled to announce the completion of this financing with support from leading investors in our industry. These funds position us well to independently advance several precision immunology programs and potentially add additional assets to our pipeline. Since the company’s launch last year, we have been making progress advancing our lead program into the clinic, initiating several pipeline programs, and leveraging insights from our analytics platform to inform both our clinical development plans and our discovery programs. Our team has expanded significantly in research, development, and business development, and we are pleased to further strengthen our board of directors with industry veterans such as Alan Colowick. I look forward to collaborating with our team and board as we work to deliver precision therapies to patients in need.”

The Gunderson deal team was led by partners Jeffrey Thacker, Ryan Gunderson, and Jonathan Spencer and associates Jordan Murray, Matthew Rietfors, and Alex Lee.